Quest for the right Drug

|
עמוד הבית / מינירין טבליות 0.2 מ"ג / מידע מעלון לרופא

מינירין טבליות 0.2 מ"ג MINIRIN TABLETS 0.2 MG (DESMOPRESSIN ACETATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליה : TABLETS

Posology : מינונים

4.2 Posology and Method of Administration
Central Diabetes Insipidus:
Tablets administration. A suitable initial dose for children and adults is 0.1 mg three times daily. The dose is than adjusted according to the response of the patient. The average daily dose is between 0.2 and 1.2 mg with tablet administration. For most patients, 0.1 – 0.2 mg three times daily is the optimal dose regimen.
Nocturnal Enuresis:
Tablets administration. A suitable initial dose is 0.2 mg at bedtime. The dose may be increased up to 0.4 mg if the lower dose is not sufficiently effective.
If treatment continues over the long-term, a treatment-free week should be introduced every three months, in order to ascertain whether the condition has resolved spontaneously.
If the desired clinical effect has not been achieved after 4 weeks of dose titration, treatment should be discontinued.


Nocturia:
The recommended initial dose is 0.1 mg at bedtime. If this does is not sufficiently effective after one week it can be increased to 0.2 mg and then to 0.4 mg by means of weekly increases. Fluid restriction is to be enforced.
In nocturic patients, a frequency/volume chart should be used to diagnose nocturnal polyuria for at least 2 days and nights before starting treatment. A night-time urine production exceeding the functional bladder capacity or exceeding 1/3 of the 24-hour urine production is regarded as nocturnal polyuria.
Serum sodium must be measured before beginning the treatment and 3 days after initiation or increase in dosage and other times during treatment as seemed necessary by the treating physician.
If adequate medical effect is not achieved within 4 weeks following appropriate dose titration the medication should be discontinued.


Assessment of the necessity of continued treatment should be made after three months during one drug- free week.
Fluid restriction should be observed, (see Special Warnings and Special Precautions for use). In the event of signs of water retention/hyponatraemia treatment should be interrupted.
שימוש לפי פנקס קופ''ח כללית 1994 Short term treatment of primary nocturnal enuresis (patients over 5 years who have the ability to concentrate urine)
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

FERRING PHARMACEUTICALS LTD

רישום

141 98 25704 01

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

20.08.20 - עלון לרופא

עלון מידע לצרכן

15.10.20 - עלון לצרכן אנגלית 01.09.15 - עלון לצרכן עברית 15.10.20 - עלון לצרכן עברית 15.10.20 - עלון לצרכן ערבית 16.03.23 - עלון לצרכן אנגלית 16.03.23 - עלון לצרכן עברית 16.03.23 - עלון לצרכן ערבית 14.06.15 - החמרה לעלון 20.08.20 - החמרה לעלון

לתרופה במאגר משרד הבריאות

מינירין טבליות 0.2 מ"ג

קישורים נוספים

RxList WebMD Drugs.com